Identification of ANKRD11 as a p53 coactivator

Journal of Cell Science

Volumn 121, Issue 21, 2008, Pages 3541-3552

  Neilsen, Paul M ^a   Cheney, Kelly M ^a   Li, Chia Wei ^b   Chen, J Don ^b   Cawrse, Jacqueline E ^a   Schulz, Renée B ^a   Powelt, Jason A ^c   Kumar, Raman ^a   Callen, David F ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c HANSON INSTITUTE   (Australia)

Author keywords

Acetylation; Ankyrin repeat domain protein; Breast cancer; p53; p53 mutant rescue

Indexed keywords

ALTERATION DEFICIENCY IN ACTIVATION PROTEIN 3; ANKYRIN REPEAT DOMAIN 11; BINDING PROTEIN; CARRIER PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA; HISTONE ACETYLTRANSFERASE PCAF; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANKRD11 PROTEIN, HUMAN; REPRESSOR PROTEIN; TP53 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MUTANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WILD TYPE; BIOLOGICAL MODEL; BREAST TUMOR; CHEMISTRY; GENETIC TRANSCRIPTION; HELA CELL; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN STRUCTURE, TERTIARY; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 59149091699     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.026351     Document Type: Article

References (48)

1. Ang, H. C., Joerger, A. C., Mayer, S. and Fersht, A. R. (2006). Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J. Biol. Chem. 281, 21934-21941.
2. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M. and Meltzer, P. S. (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968.
3. Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D. and Berger, S. L. (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243-1254.
4. Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P. and Boeke, J. D. (1998). Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17, 1847-1859.
5. Bullock, A. N. and Fersht, A. R. (2001). Rescuing the function of mutant p53. Nat. Rev. Cancer 1, 68-76.
6. Bullock, A. N., Henckel, J. and Fersht, A. R. (2000). Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245-1256.
7. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W. and Vogelstein, B. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501.
8. Bykov, V. J., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G. and Selivanova, G. (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288.
9. Di Stefano, V., Soddu, S., Sacchi, A. and D'Orazi, G. (2005). HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene 24, 5431-5442.
10. Dreyfus, D. H., Nagasawa, M., Gelfand, E. W. and Ghoda, L. Y. (2005). Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors. BMC Immunol. 6, 12.
11. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
12. Feki, A., Jefford, C. E., Berardi, P., Wu, J. Y., Cartier, L., Krause, K. H. and Irminger-Finger, I. (2005). BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase. Oncogene 24, 3726-3736.
13. Foster, B. A., Coffey, H. A., Morin, M. J. and Rastinejad, F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510.
14. Goardon, N., Lambert, J. A., Rodriguez, P., Nissaire, P., Herblot, S., Thibault, P., Dumenil, D., Strouboulis, J., Romeo, P. H. and Hoang, T. (2006). ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. EMBO J. 25, 357-366.
15. Gong, G., DeVries, S., Chew, K. L., Cha, I., Ljung, B. M. and Waldman, F. M. (2001). Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin. Cancer Res. 7, 2410-2414.
16. Gorina, S. and Pavletich, N. P. (1996). Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001-1005.
17. Gu, W. and Roeder, R. G. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606.
18. Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W. and Pandolfi, P. P. (2000). The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2, 730-736.
19. Hearnes, J. M., Mays, D. J., Schavolt, K. L., Tang, L., Jiang, X. and Pietenpol, J. A. (2005). Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol. Cell. Biol. 25, 10148-10158.
20. Juven, T., Barak, Y., Zauberman, A., George, D. L. and Oren, M. (1993). Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8, 3411-3416.
21. Kashuba, E., Mattsson, K., Klein, G. and Szekely, L. (2003). p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes. Mol. Cancer 2, 18.
22. Kochetkova, M., McKenzie, O. L., Bais, A. J., Martin, J. M., Secker, G. A., Seshadri, R., Powell, J. A., Hinze, S. J., Gardner, A. E., Spendlove, H. E. et al. (2002). CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Res. 62, 4599-4604.
23. Kumar, R., Neilsen, P. M., Crawford, J., McKirdy, R., Lee, J., Powell, J. A., Saif, Z., Martin, J. M., Lombaerts, M., Cornelisse, C. J. et al. (2005). FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res. 65, 11304-11313.
24. Kumar, R., Manning, J., Spendlove, H. E., Kremmidiotis, G., McKirdy, R., Lee, J., Millband, D. N., Cheney, K. M., Stampfer, M. R., Dwivedi, P. P. et al. (2006). ZNF652, a novel zinc finger protein, interacts with the putative breast tumor suppressor CBFA2T3 to repress transcription. Mol. Cancer Res. 4, 655-665.
25. Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16.
26. Liu, G. and Chen, X. (2006). Regulation of the p53 transcriptional activity. J. Cell Biochem. 97, 448-458.
27. Miller, B. J., Wang, D., Krahe, R. and Wright, F. A. (2003). Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am. J. Hum. Genet. 73, 748-767.
28. Nag, A., Germaniuk-Kurowska, A., Dimri, M., Sassack, M. A., Gurumurthy, C. B., Gao, Q., Dimri, G., Band, H. and Band, V. (2007). An essential role of human Ada3 in p53 acetylation. J. Biol. Chem. 282, 8812-8820.
29. Park, D. J., Nakamura, H., Chumakov, A. M., Said, J. W., Miller, C. W., Chen, D. L. and Koeffler, H. P. (1994). Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9, 1899-1906.
30. Powell, J. A., Gardner, A. E., Bais, A. J., Hinze, S. J., Baker, E., Whitmore, S., Crawford, J., Kochetkova, M., Spendlove, H. E., Doggett, N. A. et al. (2002). Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics 80, 303-310.
31. Prasad, K. A. and Church, J. G. (1997). Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells. Biochem. Biophys. Res. Commun. 232, 14-19.
32. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W. and Appella, E. (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831-2841.
33. Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Strom, M., Groner, B., Grafstrom, R. C. and Wiman, K. G. (1997). Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3, 632-638.
34. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H. et al. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014.
35. Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S. and McMahon, S. B. (2006). Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24, 841-851.
36. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. and Gu, W. (2008). Acetylation is indispensable for p53 activation. Cell 133, 612-626.
37. Toledo, F. and Wahl, G. M. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923.
38. Utku, Y., Dehan, E., Ouerfelli, O., Piano, F., Zuckermann, R. N., Pagano, M. and Kirshenbaum, K. (2006). A peptidomimetic siRNA transfection reagent for highly effective gene silencing. Mol. Biosyst. 2, 312-317.
39. Vogelstein, B., Lane, D. and Levine, A. J. (2000). Surfing the p53 network. Nature 408, 307-310.
40. Wang, T., Kobayashi, T., Takimoto, R., Denes, A. E., Snyder, E. L., el-Deiry, W. S. and Brachmann, R. K. (2001). hADA3 is required for p53 activity. EMBO J. 20, 6404-6413.
41. Watts, G. S., Oshiro, M. M., Junk, D. J., Wozniak, R. J., Watterson, S., Domann, F. E. and Futscher, B. W. (2004). The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia 6, 187-194.
42. Wei, C. L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z. et al. (2006). A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207-219.
43. Wu, X., Li, H. and Chen, J. D. (2001). The human homologue of the yeast DNA repair and TFIIH regulator MMS19 is an AF-1-specific coactivator of estrogen receptor. J. Biol. Chem. 276, 23962-23968.
44. Wysocka, J., Reilly, P. T. and Herr, W. (2001). Loss of HCF-1-chromatin association precedes temperature-induced growth arrest of tsBN67 cells. Mol. Cell. Biol. 21, 3820- 3829.
45. Yakovlev, A. G., Di Giovanni, S., Wang, G., Liu, W., Stoica, B. and Faden, A. I. (2004). BOK and NOXA are essential mediators of p53-dependent apoptosis. J. Biol. Chem. 279, 28367-28374.
46. Zhang, A., Yeung, P. L., Li, C. W., Tsai, S. C., Dinh, G. K., Wu, X., Li, H. and Chen, J. D. (2004). Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J. Biol. Chem. 279, 33799-33805.
47. Zhang, A., Li, C. W. and Chen, J. D. (2007a). Characterization of transcriptional regulatory domains of ankyrin repeat cofactor-1. Biochem. Biophys. Res. Commun. 358, 1034-1040.
48. Zhang, A., Li, C. W., Tsai, S. C. and Chen, J. D. (2007b). Subcellular localization of ankyrin repeats cofactor-1 regulates its corepressor activity. J. Cell. Biochem. 101, 1301-1315.